高级检索
当前位置: 首页 > 详情页

Mucin 1 downregulation impairs the anti-necroptotic effects of glucocorticoids in human bronchial epithelial cells

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol,Dept Resp & Crit Care Med,Key Lab Pulm Dis,Hlth Minist,Tongji Hosp,Tongji Med Coll,Wuhan 430030,Hubei,Peoples R China
出处:
ISSN:

关键词: MUC1 Necroptosis Glucocorticoid resistance Nuclear translocation P-p65

摘要:
Aims: To investigate whether mucin 1 (MUC1) downregulation reduced the sensitivity of tumor necrosis factor-alpha (TNF-alpha)-induced bronchial epithelial cells to glucocorticoid-mediated necroptosis and explore the underlying mechanisms. Main methods: The human lung bronchial epithelial cell line (16HBE) was transfected with small interfering RNA (siRNA) against MUC1 and then stimulated by TNF-alpha, where some cells were pretreated with dexamethasone. Flow cytometry was performed to analyze necroptosis in 16HBE cells, and western blot analysis was used to detect protein expression levels of MUC1, glucocorticoid receptor (GR)alpha, GR beta, NF-kappa B p65, phospho-p65 (p-p65), and histone deacetylase-2 (HDAC2). Additionally, nuclear translocation of MUC1 and GR alpha was assessed by immunofluorescence. Key findings: We observed that MUC1 downregulation by siRNA significantly augmented TNF-alpha-induced necroptosis in 16HBE cells, and that dexamethasone showed impaired anti-necroptotic effects of MUC1 downregulation. Furthermore, we found that GR alpha nuclear translocation was inhibited in 16HBE cells with MUC1 downregulation, and that dexamethasone-mediated inhibition of p65 phosphorylation was lower in cells transfected with MUC1-siRNA compared to those transfected with negative control siRNA. Significance: Impaired GR alpha nuclear translocation and inhibited p-p65 expression might contribute to glucocorticoid resistance caused by MUC1 deficiency in TNF-alpha-induced necroptosis in 16HBE cells, and should be considered as a potential target for the development of novel therapeutics for asthma.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 3 区 医学
小类 | 3 区 医学:研究与实验 3 区 药学
最新[2025]版:
大类 | 3 区 医学
小类 | 2 区 药学 3 区 医学:研究与实验
JCR分区:
出版当年[2017]版:
Q2 PHARMACOLOGY & PHARMACY Q2 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol,Dept Resp & Crit Care Med,Key Lab Pulm Dis,Hlth Minist,Tongji Hosp,Tongji Med Coll,Wuhan 430030,Hubei,Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:428 今日访问量:0 总访问量:412 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)